<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142790</url>
  </required_header>
  <id_info>
    <org_study_id>LY-TM-LPS-2014-02</org_study_id>
    <nct_id>NCT02142790</nct_id>
  </id_info>
  <brief_title>Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      This is a open-label study in patients with metastatic breast cancer to evaluate the
      antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to
      3-weekly regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel liposome injection weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel liposome injection every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel liposome injection</intervention_name>
    <arm_group_label>paclitaxel liposome injection weekly</arm_group_label>
    <arm_group_label>paclitaxel liposome injection every 3 weeks</arm_group_label>
    <other_name>LIPUSU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or Male &gt;18 years of age and &lt; 70years of age, If female of childbearing
             potential, pregnancy test is negative before first dose of study drug and agree to use
             an acceptable method of birth control to avoid pregnancy for the duration of the study

          -  Stage IV disease

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  Suitable for the treatment with paclitaxel as single agent regimen (first line or
             prior first line chemotherapy including adriamycin is allowed, If a taxane was part of
             the adjuvant regimen, at least one year should have transpired since completion of
             taxane regimen and if Her2+ patient, Herceptin therapy will be allowed.

          -  Patient has the following values at Baseline: Absolute neutrophil count ≥ 1.5 x
             10^9cells/L; platelets ≥ 100 x 10^9 cells/L; hemoglobin ≥ 10 g/dL. Aspartate
             transaminase (AST or SGOT), alanine aminotransferase (ALT or SGPT) ≤ 2.5x upper limit
             of normal range (ULN); total bilirubin ≤ 1.5ULN; creatinine ≤ 1.5 mg/dL.

          -  Informed consent has been obtained.

        Exclusion Criteria:

          -  Parenchymal brain metastases.

          -  History of other malignancy within the last 3 years

          -  New York Heart Association (NYHA) Grade 2 or greater congestive heart failure,history
             of myocardial infarction or unstable angina or new occured angina within 6 months
             prior to study enrollment.

          -  Concurrent other anticancer therapy.

          -  History of serious organic disorders (including active infection or Cardiovascular
             disease), serious hepatic disease, serious blood coagulation diseases, cachexia

          -  Sensory neuropathy of &gt; Grade 1 at baseline.

          -  Patients with prior hypersensitivity to paclitaxel

          -  Pregnant or nursing women

          -  enrolled in a different clinical study

          -  No psychiatric illness and other situations that would limit compliance of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quchang Ouyang, MD</last_name>
    <email>oyqc1969@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quchang Ouyang, MD</last_name>
      <email>oyqc1969@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>July 20, 2014</last_update_submitted>
  <last_update_submitted_qc>July 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

